Announced details
Third-line treatment for pancreatic cancer, other cancer immunotherapy areas, and research into novel COVID-19 treatments
The primary endpoint of the 3-month progression-free survival rate was achieved in the CBP501 Phase 2 trial.
SBI SECURITIES Co., Ltd. is the allottee of the stock acquisition rights and the lender under the financing. CanBas and University of Shizuoka are conducting joint research on a dual IDO/TDO inhibitor. CanBas and INTAGE Healthcare are conducting joint research on drug discovery using AI. The license agreement for CBS9106 with Stemline has been terminated, and all rights have been returned.
Detailed company profiles for SBI SECURITIES Co., Ltd., University of Shizuoka, INTAGE Healthcare, and Stemline are largely not provided. University of Shizuoka is a joint research partner.
Patents for the IDO/TDO dual inhibitor have been granted in Japan and the United States. Patent numbers and expiry dates are Not disclosed. CBP501 has received orphan drug designation in Europe and the United States. Registration numbers and expiry dates are Not disclosed.
2-2-1 Otemachi, Numazu, Shizuoka, Japan
Expected proceeds of ¥4,175 million, after deducting ¥22 million in issuance costs. The financing facility limit is ¥500 million. Upfront payments under the CBS9106 agreement were ¥10 million and ¥5 million, and cumulative technical advisory fees were ¥702 million.
For the fiscal year ended June 2026, no business revenue was recorded. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. The disclosure states that additional basic research on CBS9106 will have no short-term impact on financial results.
The company does not address Offering price.
Clinical Trials Information System (CTIS), ECIS (European Cancer Information System), Globocan 2022, IARC GLOBOCAN2018, various medical papers, ESMO2020, and the American Society of Health-System Pharmacists (ASHP), among others
| Item | Details |
|---|---|
| Names of Products / Services Covered | CBP501, CBT005, CBS9106, CBP-A08, IDO/TDO dual inhibitor |
| Counterparty | 株式会社SBI証券, Shizuoka Prefectural University, INTAGE Healthcare, Stemline |
| Counterparty overview | Detailed company profiles for SBI SECURITIES Co., Ltd., University of Shizuoka, INTAGE Healthcare, and Stemline are largely not provided. University of Shizuoka is a joint research partner. |
| Relationship with the Company | SBI SECURITIES Co., Ltd. is the allottee of the stock acquisition rights and the lender under the financing. CanBas and University of Shizuoka are conducting joint research on a dual IDO/TDO inhibitor. CanBas and INTAGE Healthcare are conducting joint research on drug discovery using AI. The license agreement for CBS9106 with Stemline has been terminated, and all rights have been returned. |
| Contract Value | Expected proceeds of ¥4,175 million, after deducting ¥22 million in issuance costs. The financing facility limit is ¥500 million. Upfront payments under the CBS9106 agreement were ¥10 million and ¥5 million, and cumulative technical advisory fees were ¥702 million. |
| Contract Date | Financing agreement date: 2 November 2026. Out-licensing of CBS9106: December 2014; expansion of the covered territory: August 2018; agreement termination and return of rights: June 2025. |
| Launch date | Approval to initiate the European Phase 3 clinical trial of CBP501 has been obtained, and preparations for initiation are under way in 8 European countries. The start date is Not disclosed. |
| Applicable area | Third-line treatment for pancreatic cancer, other cancer immunotherapy areas, and research into novel COVID-19 treatments |
| Registration number and expiry date | Patents for the IDO/TDO dual inhibitor have been granted in Japan and the United States. Patent numbers and expiry dates are Not disclosed. CBP501 has received orphan drug designation in Europe and the United States. Registration numbers and expiry dates are Not disclosed. |
| Location | 2-2-1 Otemachi, Numazu, Shizuoka, Japan |
| Location scale | 19 employees, comprising 14 in research and development and 5 in administration. The CBP501 Phase 3 trial is planned to involve approximately 50 sites in 8 countries, with approximately 180 participants in total across 2 groups. |
| Quantitative Effects | The primary endpoint of the 3-month progression-free survival rate was achieved in the CBP501 Phase 2 trial. |
| Impact on Business Performance | For the fiscal year ended June 2026, no business revenue was recorded. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. The disclosure states that additional basic research on CBS9106 will have no short-term impact on financial results. |
| Source | Clinical Trials Information System (CTIS), ECIS (European Cancer Information System), Globocan 2022, IARC GLOBOCAN2018, various medical papers, ESMO2020, and the American Society of Health-System Pharmacists (ASHP), among others |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To explain the company profile, research and development progress, financing, and financial position to investors.